Ekonomi Bölümü Koleksiyonu
Permanent URI for this collectionhttps://hdl.handle.net/20.500.11779/1936
Browse
41 results
Search Results
Article Citation - Scopus: 24Epidemiology and Economic Burden of Serotonin Syndrome With Concomitant Use of Serotonergic Agents: a Retrospective Study Utilizing Two Large Us Claims Databases(Physicians Postgraduate Press Inc., 2017-12-28) Alley, Stephanie; Nguyen, Charles T.; McCarron, Robert M.; Wang, Zhixiao; Xie, Lin; Başer, OnurObjective: Serotonin syndrome (SS) is an adverse drug reaction occurring among patients receiving serotonergic agents (SAs), and although SAs are commonly prescribed, the epidemiology and economic burden of SS with concomitant SA use have not been comprehensively examined. The objective of this study was to investigate the prevalence, incidence, and economic burden of SS with SA use. Methods: A retrospective cohort study was conducted using Veterans Health Administration (VHA) records (identification period: October 1, 2008-September 30, 2012) and commercially insured patient records (Intercontinental Marketing Services PharMetrics Plus; identification period: January 1, 2010-December 31, 2013). Cohorts were based on drug classification and exposure: single monoamine oxidase inhibitor (MAOI), MAOIs in combination with SAs, single non-MAOI SA, and multiple non-MAOI SAs (2, 3, 4, ? 5). Participants were aged ? 18 years with continuous health plan enrollment for 12 months prior to the first SA claim. Outcomes were SS events (ICD-9-CM: 333.99), annual incidence and prevalence, related health care utilization and costs, and SS incidence relative risk. Results: Over 15 million patients were identified and categorized by SA prescription type. SS incidence in both populations decreased: 0.19%-0.07% (VHA) and 0.17%-0.09% (commercially insured). Overall SS prevalence decreased during the study period. Compared to single non-MAOI SA patients, SS incidence relative risk was highest among patients prescribed ? 5 non-MAOI SAs. Inpatient stays accounted for 4.35% (VHA) and 0.88% (commercially insured) of all SS events. Of SS-related inpatient stays, median costs were $8,765 (VHA) and $10,792 (commercially insured). Conclusions: SS incidence and prevalence and SS-related hospitalization risk among patients prescribed SAs were low in both populations. This study provides additional information regarding SS risk associated with SA use. © 2017, Physicians Postgraduate Press Inc. All rights reserved.Conference Object Evaluating the Economic Burden and Health Care Utilization of Coronary Artery Disease in the Us Medi-Cal Population(2016) Zhang, Q; Zhao, Y; Keshishian, A; Xie, L; Yuce, H; Başer, Onur...Conference Object A Comparative Analysis of the Health Care Utilization and Costs of Patients Diagnosed With and Without Liver Cancer in the Us Medicare Population(2017) Ogbomo, A.; Lin, Y.; Keshishian, A; Xie, L; Yuce, H; Başer, Onur...Conference Object Trends in Prevalence and Incidence Rates of Type 2 Diabetes Mellitus in the Medicare Population(2015) Xie, L; Wang, Y; Tan, H; Ogbomo, A; Başer, Onur; Yuce H....Conference Object Mortality and Rehospitalization Rates Among Hospitalized Congestive Heart Failure Patients in the Us Medicare Population(2016) Pandya S; Du, H; Wang, L; Yuce, H; Başer, Onur...Conference Object Demographic and Clinical Characteristics of Patients With Polycythemia Vera (pv) in the Us Veterans Population(2016) Parasuraman S; Yu J; Paranagama D; Shrestha S; Wang L,; Başer, Onur...Conference Object Examining the Incidence and Prevalence of Bipolar Disorder Among U.s. Veteran Patients From 2011 To 2015(2016) Bashyal, R; Du, H; Wang, L; Başer, Onur...Conference Object Examining the Incidence and Prevalence of Alcohol Dependence Among Us Veteran Patients(2016) Bashyal, R; Du, H; Wang, L; Başer, Onur...Conference Object The Role of Stakeholder Engagement in E-Health and the Use of Big Data To Predict Health Outcomes(2017) Cinaroğlu, S.; Başer, Onur...Conference Object Comparison of Major-Bleeding Risk and Health Care Costs Among Treatment-Naïve Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin(2015) Amin, Alpesh; Keshishian, A; Xie, L; Başer, Onur; Price, K; Vo, L; Singh, P; Bruno, A; Mardekian, J; Tan, W; Singhal, S; Patel, C; Odell, K; Trocio J....